Spectroscopic, Electrochemical, Computational, and Biological Investigation of Cu(II), Ni(II), and Zn(II) Complexes of 3-Pyridinecarboxaldehyde Thiosemicarbazone
The new 3-pyridinecarboxaldehyde-based thiosemicarbazone ligand 3-PCTSC and its Cu(II), Ni(II), and Zn(II) complexes were successfully prepared and well characterized in terms of molecular structure, electronic structure, and biological activity. The DNA and BSA binding were investigated through PL and CV, and found to be strong and spontaneous binding (hypothesized to be static quenching) within the molecules. The binding number was highest for the Ni(II) complexes, elucidated to derive from an elongated conjugated system with more electron cloud density and more charge transfer ability; this trend was borne out in the biological activity studies. Electronic distributions and reactive areas characterized through DFT, the ring structures, and frontier molecular orbital evaluation showed good correlation with the bioactivity results. The molecular dockings against the BSA, DNA, and some cancer target proteins produced binding energies that were very promising, with the Ni(II) compound exhibiting the most thermodynamically favorable binding modes with hydrogen bonding, stacking interactions, and metal adjacent binding modes. ADMET calculations gave all the molecules excellent druglikeness, acceptable lipophilicity, high GI absorption, and no abnormal toxic alerts. Due to all these factors, this Ni(II) derivative was the most cytotoxic in an 'in vitro' screening experiment, and more than ten times the potency of the ligand alone and the other two analogues. In summary, the spectroscopic, electrochemical, computational, and biological data altogether unveil the great anticancer efficacy of the nickel(II) complex.